SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today clinical findings using non-invasive CyberKnife ® stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer. Two studies presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston were selected by ASTRO for presentation to the media at a prostate-focused press conference on Tuesday, October 30, 2012, for which the use of CyberKnife SBRT for prostate cancer represented half of the press conference's focus.
During ASTRO's Scientific Sessions, data on CyberKnife prostate SBRT for organ-confined prostate cancer was presented in the form of three podium presentations and seven poster presentations by researchers from leading U.S. academic and community-based cancer treatment centers. In these studies, all patients were treated in five or fewer, non-surgical outpatient treatment sessions – far fewer than the 40 or more patients typically receive with traditional radiotherapy or intensity modulated radiation therapy (IMRT). Overall, efficacy and toxicity findings compared favorably with longer courses of IMRT, expanding the foundation of evidence supporting the value of CyberKnife prostate SBRT for patients with organ confined prostate cancer.
Below is an overview of the three CyberKnife prostate studies selected for podium presentation by ASTRO's Review Committee:
Alan J. Katz, M.D., a radiation oncologist with Flushing Radiation Oncology in Flushing, N.Y., presented findings from a multi-center study, organized by researchers at UCLA Medical Center, of outcomes for 1,100 low, intermediate and high-risk prostate cancer treated with CyberKnife SBRT at eight centers within the United States and Italy.Patients were followed for a median of 36 months, and close to half were followed for at least four years, as updated by Dr. Katz during his presentation. Actuarial five-year disease-free survival was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients. These findings compare favorably with other surgical and radiation-based treatments.